While antibiotics may offer certain cardiometabolic benefits by modulating gut microbiota, their widespread use remains debatable due to potential risks
Your Options Request a formulary exception your doctor can argue medical necessity What to do if Wegovy is not covered Cardiovascular risk reduction if you have heart disease risk factors, Wegovy's FDA-approved indication (March 2024) strengthens your case Consider Zepbound as of October 1, 2026 it returns as an "additional preferred option" alongside Wegovy on most Aetna/CVS Caremark plans [10] Zepbound coverage on Aetna Switch plans during open enrollment if your employer offers multiple options, check for GLP-1 coverage Explore self-pay options NovoCare ($349/mo) and patient assistance may help Wegovy Cost Guide About Wegovy's FDA Approvals Important: Sleep Apnea Coverage Goes to Zepbound, Not Wegovy Note: Zepbound (tirzepatide), not Wegovy, was FDA-approved to treat obstructive sleep apnea (OSA) in adults with obesity on December 20, 2024
To reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least one weight-related comorbid condition
Active or recent malignancy is treated as a hard contraindication in the clinical literature, and a history of hormone-sensitive cancer warrants specialist input
It shows a decline in snack consumption linked to increasing use of GLP-1 medications, with the studys final sample representing an 11.6% incidence
exclusivity (Times of India, 2025), mirror Indias aggressive generic strategy
